Nicholas Company Inc. Has $16.59 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Nicholas Company Inc. boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 84,404 shares of the medical research company’s stock after acquiring an additional 303 shares during the period. Nicholas Company Inc.’s holdings in IQVIA were worth $16,586,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Private Trust Co. NA lifted its position in IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after acquiring an additional 47 shares during the last quarter. Pine Valley Investments Ltd Liability Co lifted its position in IQVIA by 0.5% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock worth $2,247,000 after acquiring an additional 50 shares during the last quarter. Howard Capital Management Inc. lifted its position in IQVIA by 4.9% during the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock worth $225,000 after acquiring an additional 54 shares during the last quarter. Huntington National Bank lifted its position in IQVIA by 7.4% during the 3rd quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock worth $192,000 after acquiring an additional 56 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its position in IQVIA by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock worth $1,068,000 after acquiring an additional 56 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Citigroup dropped their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday. UBS Group dropped their price objective on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Leerink Partners restated an “outperform” rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Price Performance

Shares of IQVIA stock opened at $185.40 on Friday. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $256.34. The firm’s 50-day moving average price is $196.63 and its two-hundred day moving average price is $210.69. The stock has a market capitalization of $32.69 billion, a price-to-earnings ratio of 24.72, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.